Literature DB >> 16779737

Clinical features in children hospitalized during the 2005 epidemic of Japanese encephalitis in Uttar Pradesh, India.

Rashmi Kumar1, Piyush Tripathi, Sudhakar Singh, Gopa Bannerji.   

Abstract

BACKGROUND: Japanese encephalitis is a disease that affects the rural poor in Asia. In August-September 2005, a severe epidemic of Japanese encephalitis occurred in Uttar Pradesh, one of India's poorest states.
METHODS: Children admitted to the King George Medical University hospital (Lucknow, Uttar Pradesh, India) with acute febrile encephalopathy (defined as fever plus encephalopathy of <or=2 weeks' duration) from July to October 2005 underwent ELISA for Japanese encephalitis virus immunoglobulin M in cerebrospinal fluid or serum on hospital admission. Clinicolaboratory features of patients with positive test results were recorded.Results. Of the 223 children tested, 77 had positive results for Japanese encephalitis immunoglobulin M. Patients were from 18 districts of Uttar Pradesh. All but 1 were from rural areas, and none were <2 years of age. The prodromal period was very short (mean+/-standard deviation, 2.61+/-2.23 days). Convulsions were present in 76 patients (98.7%). The mean (+/- standard deviation) Glasgow Coma Scale score was 7.4+/-2.7. Generalized hypertonia was found in 39 patients (50.6%), and focal deficits were found in 35 patients (45.4%), including 19 cases of monoparesis and 16 cases of hemiparesis. Gastric hemorrhage was found in 42 patients (54.5%). Extrapyramidal features were found in 24 (31.1%), a hyperepneic breathing pattern was found in 20 (26%), and thrombocytopenia was found in 5 (15.6%) of 32 patients. The mean cerebrospinal fluid cell count was 48.3 cells/mm(3). The serum bilirubin level was normal in all patients, but the aspartate aminotransferase level was elevated in all 21 patients (100%) tested and the alanine aminotranferase level was elevated in 25 (47.2%) of 53 patients. In-hospital mortality was 34%.
CONCLUSIONS: Clinical features of Japanese encephalitis were severe. Derangements in liver function and thrombocytopenia were found in a significant proportion of patients. These findings were not highlighted during earlier epidemics of the illness and could suggest a possible mutation of the virus towards other flaviviruses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16779737     DOI: 10.1086/505121

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  35 in total

Review 1.  Emergence of the severe syndrome and mortality associated with dengue and dengue-like illness: historical records (1890 to 1950) and their compatibility with current hypotheses on the shift of disease manifestation.

Authors:  Goro Kuno
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

2.  A replication-defective Japanese encephalitis virus (JEV) vaccine candidate with NS1 deletion confers dual protection against JEV and West Nile virus in mice.

Authors:  Na Li; Zhe-Rui Zhang; Ya-Nan Zhang; Jing Liu; Cheng-Lin Deng; Pei-Yong Shi; Zhi-Ming Yuan; Han-Qing Ye; Bo Zhang
Journal:  NPJ Vaccines       Date:  2020-08-05       Impact factor: 7.344

3.  Japanese encephalitis (JE). Part I: clinical profile of 1,282 adult acute cases of four epidemics.

Authors:  N B S Sarkari; A K Thacker; S P Barthwal; V K Mishra; Shiv Prapann; Deepak Srivastava; M Sarkari
Journal:  J Neurol       Date:  2011-06-17       Impact factor: 4.849

4.  Clinical and etiological profile of acute febrile encephalopathy in eastern Nepal.

Authors:  Rupa R Singh; S K Chaudhary; Nisha K Bhatta; B Khanal; Dheeraj Shah
Journal:  Indian J Pediatr       Date:  2009-11       Impact factor: 1.967

5.  Concurrent infection of Japanese encephalitis and mixed plasmodium infection.

Authors:  Girish Chandra Bhatt; Tanya Sharma; K P Kushwaha
Journal:  J Pediatr Neurosci       Date:  2012-01

Review 6.  Risk assessment for Japanese encephalitis vaccination.

Authors:  Lance Turtle; Carolyn Driver
Journal:  Hum Vaccin Immunother       Date:  2017-12-21       Impact factor: 3.452

7.  Overview of Japanese encephalitis disease and its prevention. Focus on IC51 vaccine (IXIARO®).

Authors:  D Amicizia; F Zangrillo; P L Lai; M Iovine; D Panatto
Journal:  J Prev Med Hyg       Date:  2018-03-30

Review 8.  Japanese encephalitis - the prospects for new treatments.

Authors:  Lance Turtle; Tom Solomon
Journal:  Nat Rev Neurol       Date:  2018-04-26       Impact factor: 42.937

9.  Development and characterization of the replicon system of Japanese encephalitis live vaccine virus SA14-14-2.

Authors:  Shi-Hua Li; Xiao-Feng Li; Hui Zhao; Yong-Qiang Deng; Xue-Dong Yu; Shun-Ya Zhu; Tao Jiang; Qing Ye; E-De Qin; Cheng-Feng Qin
Journal:  Virol J       Date:  2013-02-26       Impact factor: 4.099

10.  Japanese encephalitis virus disrupts cell-cell junctions and affects the epithelial permeability barrier functions.

Authors:  Tanvi Agrawal; Vats Sharvani; Deepa Nair; Guruprasad R Medigeshi
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.